Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12297020 | 0.86 | ALDH1A1 (0.69) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL6983366 | 0.85 | ALDH1A1 (0.68) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL6983363 | 0.85 | ALDH1A1 (0.68) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL5605709 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL7400389 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL19195034 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL1720494 | 0.82 | MAPT (0.72) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL5605913 | 0.82 | MAPT (0.69) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL2607028 | 0.82 | POLB (0.65) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL2415496 | 0.82 | ALDH1A1 (0.64) | ALDH1A1MAPTMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2125038-B1 | RADIOACTIVE PET AGENTS FOR IMAGING CCR5 IN VIVO | GE HEALTHCARE LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20110129419-A1 | IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110129419-A1 | IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| WO-2008075040-A2 | IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129419-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | ALDH1A1 2886/4885MAPT 2813/4885MEN1 1111/4885 |
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | ALDH1A1 2886/4885MAPT 2813/4885MEN1 1111/4885 |
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | ALDH1A1 2886/4885MAPT 2813/4885MEN1 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.